Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Verstraeten

Showing results (1-10 of 78) with videos related to

Pageof 8
Sort By:
Pediatrics|April 3, 2004
Thimerosal, the Centers for Disease Control and Prevention, and GlaxoSmithKlineThomas Verstraeten
Vaccine|May 12, 2009
Rebuttal Letter to the Letter to the Editor to "Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines" by T. Verstraeten et alThomas Verstraeten
Clinical Epidemiology|May 3, 2021
Estimation of Risk of Death Attributable to Acute Gastroenteritis Not Caused by <i>Clostridioides difficile</i> Infection Among Hospitalized Adults in EnglandMaria Alexandridou, Tom Cattaert, Thomas Verstraeten
Vaccine: X|August 7, 2019
Risk factors for modified vaccine effectiveness of the live attenuated zoster vaccine among the elderly in EnglandKaatje Bollaerts, Maria Alexandridou, Thomas Verstraeten
Human Vaccines|July 21, 2009
Quantitative signal detection for vaccines: effects of stratification, background and masking on GlaxoSmithKline's spontaneous reports databaseZiad Zeinoun, Harry Seifert, Thomas Verstraeten
Vaccine|November 26, 2018
Observational studies of non-specific effects of Diphtheria-Tetanus-Pertussis vaccines in low-income countries: Assessing the potential impact of study characteristics, bias and confounding through meta-regressionKaatje Bollaerts, Thomas Verstraeten, Catherine Cohet
The Journal of Infection|February 13, 2021
Decrease in norovirus infections in Germany following COVID-19 containment measuresUlrich Eigner, Thomas Verstraeten, John Weil
Vaccine|June 11, 2018
A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among older adultsMarc Baay, Kaatje Bollaerts, Thomas Verstraeten
BMC Infectious Diseases|March 18, 2026
Correction: Model estimates of hospitalization discharge rates for norovirus gastroenteritis in Europe, 2004-2015Elsa Negro-Calduch, Tom Cattaert, Thomas Verstraeten
Expert Review of Vaccines|August 7, 2003
Hepatitis B vaccine and risk of multiple sclerosisFrank DeStefano, Thomas Verstraeten, Robert T Chen
Pageof 8

Showing results (1-10 of 78) with videos related to

Sort By:
Pageof 8
Pediatrics|April 3, 2004
Thimerosal, the Centers for Disease Control and Prevention, and GlaxoSmithKlineThomas Verstraeten
Vaccine|May 12, 2009
Rebuttal Letter to the Letter to the Editor to "Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines" by T. Verstraeten et alThomas Verstraeten
Clinical Epidemiology|May 3, 2021
Estimation of Risk of Death Attributable to Acute Gastroenteritis Not Caused by <i>Clostridioides difficile</i> Infection Among Hospitalized Adults in EnglandMaria Alexandridou, Tom Cattaert, Thomas Verstraeten
Vaccine: X|August 7, 2019
Risk factors for modified vaccine effectiveness of the live attenuated zoster vaccine among the elderly in EnglandKaatje Bollaerts, Maria Alexandridou, Thomas Verstraeten
Human Vaccines|July 21, 2009
Quantitative signal detection for vaccines: effects of stratification, background and masking on GlaxoSmithKline's spontaneous reports databaseZiad Zeinoun, Harry Seifert, Thomas Verstraeten
Vaccine|November 26, 2018
Observational studies of non-specific effects of Diphtheria-Tetanus-Pertussis vaccines in low-income countries: Assessing the potential impact of study characteristics, bias and confounding through meta-regressionKaatje Bollaerts, Thomas Verstraeten, Catherine Cohet
The Journal of Infection|February 13, 2021
Decrease in norovirus infections in Germany following COVID-19 containment measuresUlrich Eigner, Thomas Verstraeten, John Weil
Vaccine|June 11, 2018
A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among older adultsMarc Baay, Kaatje Bollaerts, Thomas Verstraeten
BMC Infectious Diseases|March 18, 2026
Correction: Model estimates of hospitalization discharge rates for norovirus gastroenteritis in Europe, 2004-2015Elsa Negro-Calduch, Tom Cattaert, Thomas Verstraeten
Expert Review of Vaccines|August 7, 2003
Hepatitis B vaccine and risk of multiple sclerosisFrank DeStefano, Thomas Verstraeten, Robert T Chen
Pageof 8